Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

Inclusion Criteria: * Histologically or cytologically confirmed advanced solid tumor * Part II only: Have a known deleterious BRCA1/2 mutation (germline or somatic) as determined by a local or central laboratory * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate bone marrow, renal, and liver function Exclusion Criteria: * Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, or angiogenesis inhibitors within 14 days prior to Day 1 * Participation in a trial involving administration of \[14C\]-labeled compound(s) within the last 6 months prior to Day 1 * Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months prior to Screening * Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib * Untreated or symptomatic central nervous system (CNS) metastases * Evidence or history of bleeding disorder * Participation in another investigational drug trial within 14 days prior to Day 1 (or 5 times the half-life of the drug, whichever is longer) or exposure to more than three new investigational agents within 12 months prior to Day 1 * Acute illness (eg, nausea, vomiting, fever, diarrhea) within 14 days prior to Day 1, unless mild in severity and approved by the Investigator and Sponsor's/designated medical representative * Active second malignancy